Current Opinion in Pediatrics Cord Blood Banking and Transplantation: Advances and Controversies

Size: px
Start display at page:

Download "Current Opinion in Pediatrics Cord Blood Banking and Transplantation: Advances and Controversies"

Transcription

1 Current Opinion in Pediatrics Cord Blood Banking and Transplantation: Advances and Controversies --Manuscript Draft-- Manuscript Number: Full Title: Article Type: Corresponding Author: Cord Blood Banking and Transplantation: Advances and Controversies Review Article Mervin C Yoder Indianapolis, IN UNITED STATES Corresponding Author Secondary Information: Corresponding Author's Institution: Corresponding Author's Secondary Institution: First Author: Mervin C Yoder First Author Secondary Information: Order of Authors: Mervin C Yoder Order of Authors Secondary Information: Powered by Editorial Manager and ProduXion Manager from Aries Systems Corporation

2 *Manuscript Cord Blood Banking and Transplantation: Advances and Controversies Mervin C. Yoder, MD Distinguished Professor and Richard and Pauline Klingler Professor of Pediatrics Department of Pediatrics Indiana University School of Medicine Indianapolis, IN Phone:

3 Abstract Purpose of review: A review of papers published since January 2012 on the topic of cord blood banking and cord blood stem cell transplantation was conducted for this the 25 th anniversary year of the first cord blood transplant performed in a human subject. Recent findings: Cord blood banking is performed throughout the world. Umbilical cord blood (UCB) transplantation is recognized as an acceptable alternative stem cell source for pediatric and adult subjects requiring a hematopoietic transplant, particularly for patients of racial and ethnic minorities. To further advance the use of UCB, methods to enhance UCB stem cell expansion, engraftment, and maintenance may be required. Controversy on the most effective and economically sustainable model for banking and storing an optimal UCB product continues to persist. Summary: Cord blood banking and transplantation of cord blood stem cells has advanced rapidly over the initial 25 years as more than 30,000 patients have benefited from the therapy. New concepts on the use of methods to expand UCB stem cells for transplantation and use for non-hematopoietic indications may increase demand for UCB over the next few decades. Keywords: Umbilical cord blood Umbilical cord blood banking Cord blood stem cell transplantation

4 Introduction This has been a notable year for cord blood transplantation and banking, since it was 25 years ago that a child with Fanconi Anemia received an umbilical cord blood (UCB) transplant. Since that time, more than 600,000 UCB units have been cryopreserved and stored in banks throughout the world and >30,000 transplants have been performed using stored material [1]. We will briefly point out some notable achievements that have occurred over the past 25 years and highlight some recent advances in cord blood transplantation. We will also point out a few areas where UCB has been proposed as a novel source of stem cells that may provide repair or regeneration of tissue function in non-hematopoietic systems. Finally, we will discuss the ongoing challenge of providing education to the public as to the different types of cord blood banks that collect and preserve UCB under different economic and blood banking standards. Overview of highlights from the first 25 years of cord blood transplantation and banking The first UCB transplant was successfully performed through the efforts of a team of international investigators [1]. A child with FA who was suffering from severe aplastic anemia was deemed a potentially suitable candidate when a tissue matched sibling was born and UCB was isolated and cryopreserved in the laboratory of Dr. Hal Broxmeyer. Dr. Arleen Auerbach determined that the UCB of the donor sibling was unaffected by FA. Dr. Eliane Gluckman had previously developed pre-transplant conditioning regimens for patients with FA, and successfully performed the UCB transplant in October of 1988 after appropriate ethics review [1, 2]. The patient displayed signs of donor cell engraftment on day 22 post-transplant and subsequently achieved a full hematopoietic reconstitution with donor cells. Now 25 years later, this healthy patient continues to show complete hematologic and immunologic donor cell chimerism [1]. Several years after this epic event, the first public UCB bank was formed at the New York Blood Center [3] and in 1993 the first unrelated UCB transplant was performed [4, 5].

5 Subsequently UCB was increasingly utilized in pediatric patients. When comparing bone marrow versus UCB as a source of matched sibling donor stem cells`, transplantation of UCB was associated with delayed neutrophil and platelet time to engraftment`, reduced acute and chronic GVHD`, but similar survival [6]. In a recent analysis of 5 year outcomes of children with acute leukemia that received a sibling UCB transplant, the probability of disease free survival (DFS) was 44% [7]. In children with acute leukemia that received either an unrelated matched UCB or an unrelated matched bone marrow transplant, recipients of the UCB had better outcomes [8]. An increase in transplant related mortality (TRM) was detected in children receiving < 3 X 10 7 total nucleated cells per kilogram bodyweight and a 1 HLA-disparate match or in children given a 2 HLA-disparate UCB transplant, pointing out the importance of UCB unit selection for improving outcomes [8]. One approach to enhancing cell dose is to provide a double UCB transplant. A preliminary analysis of a clinical study directly comparing the use of a single versus a double UCB transplant in pediatric patients with a hematologic malignancy did not show a survival advantage [1, 9]. Use of UCB as a stem cell source in adult patients with leukemia failed to result in the promising results obtained in pediatric patients with concerns that the neutrophil and platelet recovery times were significantly delayed and there was high TRM [10]. However, improvements in patient selection, better supportive care, and the use of higher infused cell dose have been associated with increased survival. A recent analysis of factors that affect mortality following myeloablative UCB transplantation in adult subjects identified older age, advanced disease, and limited center experience correlated with worse survival [11]. However, a remarkable 60-70% 5 year DFS was reported by one group from Japan for adult patients with acute myelogenous leukemia (AML) that underwent myeloablative conditioning prior to receiving a single UCB transplant [12]. To improve outcomes in the United States, combining reduced intensity conditioning with double cord blood transplantation has resulted in 30-50% DFS in adult subjects with malignancy [13, 14]. Improvements in UCB unit selection are expected to

6 further enhance outcomes in adult subjects that need an UCB transplant [15]. Thus, one recent review recommends that UCB transplantation should be considered in all high-risk adult subjects with AML in whom an allogeneic stem cell transplant is indicated but who lack a matched related or unrelated donor [1]. Methods to expand UCB hematopoietic stem cells Given the delayed donor cell reconstitution of UCB recipients and the associated increased incidence of late viral infections and other TRM [16], strategies to enhance the numbers of transplanted stem cells in each UCB unit have long been desired [17, 18]. Results from recent clinical trials testing the safety and feasibility of expanding an UCB unit ex vivo and then infusing with a second unmanipulated UCB unit have been reported. Notch-mediated expansion of UCB capable of rapid myeloid reconstitution Activation of endogenous Notch receptors on UCB CD34 + cells via co-culture on immobilized engineered Delta-like ligand 1 was known to increase the CD34 + content nearly 100-fold and to increase the engraftment of the Notch activated cells in immunodeficient mice [19]. In preliminary clinical studies, use of the same approach provided a significant expansion of UCB CD34 + cells and when co-infused with an unmanipulated UCB unit, reduced the time to an absolute neutrophil count (ANC) >500 cells per L to a median of 16 days. This time was significantly reduced compared to a median of 26 days for ANC recovery in patients concurrently treated at the same institution with a double UCB transplant [20]. A recent update to that report indicates that 17 patients have now been enrolled and the median time to ANC recovery has been shortened to 11 days compared to 25 days in a concurrently enrolled institutional cohort of 36 patients undergoing a double UCB transplant [18]. Since the expanded unit predominated during the first week post-transplant, evidence exists that the Notch activated UCB cells provide rapid myeloid recovery.

7 UCB engraftment with ex vivo mesenchymal-cell co-culture Expansion of hematopoietic progenitor cells in unfractionated UCB cells has been known to be markedly enhanced upon co-culture with mesenchymal stromal cells [21]. In a recent report, 31 adult subjects with hematological cancer that received an UCB transplant with 1 expanded unit and 1 unmanipulated unit were compared to 80 historical control subjects who received 2 unmanipulated UCB units. The median time to neutrophil engraftment was 15 days in the patients that received the expanded unit plus the unmanipulated unit compared to 24 days in the control patients that received a double UCB unit transplant; a significant improvement [22]. The median time to platelet recovery was also significantly shortened from 49 days in the control patients to 42 days in the patients receiving the expanded plus unmanipulated UCB. Of interest, the dose of the CD34 + cells and total nucleated cells per kilogram bodyweight in the recipients of the expanded unit significantly correlated with the time to neutrophil recovery. Long-term engraftment of more than 1 year was produced primarily by the unit of unmanipulated UCB in these patients. These results support the hypothesis that transplantation of UCB cells expanded with mesenchymal cells shortens the time to neutrophil and platelet recovery in adult subjects [22]. Other approaches to expand UCB A variety of other approaches have been examined for expanding human UCB cells. One approach expands a portion of an UCB unit using selected growth factors in the presence of a copper chelating agent tetraethylpentamine and this strategy appeared to enhance single UCB engraftment in a phase I/II clinical trial [23]. A number of preclinical studies have provided promising pathways to expand UCB. A purine molecule name StemRegenin1 (SR1) was identified in an unbiased screen of 100,000 compounds to expand CD34 + cells. UCB cells treated with SR1 demonstrated a 50-fold increase in CD34 + cells and a 17-fold increase in UCB cells that repopulate immunodeficient mice and may be one promising agent to expand UCB [24]. In another approach, human umbilical vein endothelial cells (HUVECs) were infected with a

8 lentivirus encoding the E4ORF1 gene of adenoviruses to permit long term culture and survival of the infected HUVECs (E4ECs) in serum free/growth factor free conditions [25]. Co-culture of UCB CD34 + cells with the E4ECs in direct contact with minimal concentrations of hematopoietic cytokines resulted in a 150-fold expansion of hematopoietic progenitor cells that was 3-fold greater than the hematopoietic cytokines alone. Significantly greater primary and secondary engraftment of the expanded UCB CD34 + cells into immunodeficient mice was observed in the cells expanded on the E4ECs than in cultures with hematopoietic cytokines alone [25]. Another group has identified CD146 + perivascular mesenchymal cells derived from human adult adipose tissue to provide in vitro co-culture support to expand the number of UCB CD34+ cells and to enhance engraftment into immunodeficient mice [26]. Other approaches have been recently reviewed [17]. In sum, a host of approaches are seeking to expand the stem cell pool within the UCB that may permit greater utilization of UCB as an alternative stem cell source for adult subjects that lack suitable donors. Methods to enhance UCB homing and engraftment One way to enhance the seeding of UCB cells into the bone marrow niches that are specialized for stem cells, is to directly inject the UCB into the bone marrow cells [27]. Time to recovery of neutrophil and platelet counts has recently been shown to be significantly shortened in a comparison of patients undergoing an intra-bone UCB transplant versus a double UCB transplant [28]. A significant reduction in acute GVHD was also reported in patients receiving the intra-bone UCB transplant [28]. However, only a prospective study that employs a homogenous conditioning regimen and GVHD prophylaxis will permit determination of whether the intra-bone UCB versus double UCB transplantation approach provides a better outcome. An alternative choice for enhancing UCB transplant outcomes would be to enhance the homing of the cells into the marrow niche. A stable prostaglandin E 2 (PGE 2 ) derivative 16,16- dimethyl PGE 2 (dmpge 2 ) has been shown to enhance hematopoietic stem cell (HSC)

9 engraftment with some evidence for increased HSC homing and survival [29-32]. In a phase I trial recently completed, dmpge 2 treatment of a single UCB unit when administered with an unmanipulated UCB unit led to accelerated neutrophil recovery compared to historical controls and the dmpge 2 treated UCB unit outcompeted the unmanipulated UCB unit long term in 10 of 12 subjects [33]. Based upon these results, the authors are proposing additional clinical trials of dmpge 2 to enhance engraftment of UCB and even autologous adult peripheral blood stem cells for transplantation. Homing of UCB cells may also be enhanced by treating the cells with fucosyltransferase- VI. UCB CD34 + cells displaying greater cell surface fucosylation displayed more rapid and higher levels of engraftment in immunodeficient mouse models compared to untreated UCB cells [34]. These results have spawned a human clinical trial in which patients will receive a double UCB unit transplant in which one of the units is fucosylated [18]. Dipeptidylpeptidase 4 (DPP4) is expressed on the cell surface of many cells, but inhibition of DPP4 on HSC enhances engraftment in preclinical studies [35]. In a recent phase I trial, patients undergoing a single unit UCB transplant were administered sitagliptin (DPP4 inhibitor) orally prior to the UCB cell infusion. Systemic DPP4 inhibition was achieved and was well tolerated. A correlation between DPP4 activity time curve and time to engraftment was observed. Optimization of the DPP4 inhibition through manipulation of the oral agent may permit improved outcomes [36]. UCB use for non-hematological disorders While the above discussion has outlined the important role UCB can play as a source of cells to repopulate the hematopoietic system in patients requiring such a therapy, UCB has been demonstrated to contain a variety of other cell types with stem cell properties [37]. Mesenchymal stem/stromal cells (MSCs), multipotent adult progenitor cells, unrestricted somatic stem cells, and endothelial colony forming cells have all been isolated and

10 cryopreserved from UCB [38]. A recent analysis of clinical trials using UCB for non-hematologic disorders has identified 31 unique trials for 15 different clinical conditions (Table) [38]. Essentially all of the clinical trials have arisen from preclinical data obtained using animal models of human disease and in many cases, UCB or UCB-derived stem cell populations as therapeutic agents. Great interest has arisen over the potential use of autologous UCB to treat human neonates that suffer hypoxic-ischemic injury [39]. Human clinical trials using this approach are underway, however, no reports of the outcomes of these trials are yet available [40]. UCB banking ongoing controversies UCB continues to be banked largely in two separate systems: public or private cord blood banks. Public banks incur all the costs for collection, transportation, processing, testing, and cryopreservation. The inventory of the UCB units is listed through national and international registries and is intended to provide patients with a high quality unit if needed and matched. If a unit is selected for transplant, the public bank is compensated as a cost-recovery. Private cord blood banks charge a fee to parents for the collection, transportation, processing, testing, and cryopreservation of the material and some type of annual fee for the ongoing storage of the UCB unit. A comparison of the public and private banking processes has recently been published [41]. Some controversy continues to exist around the cost-effectiveness of the private UCB banking system. One study has argued that use of autologous UCB units from private cord blood banks is extremely rare compared to use of allogeneic units from public banks and overall this leads to a much higher cost per unit used from the private over public banks [4, 42]. Furthermore, given the fact that most private banks are not subject to the same regulatory review as public banks, one cannot be assured that the UCB stored is of comparable quantity and quality when comparing private to public units. Hybrid UCB banking models have been

11 considered but also suffer from many ethical, regulatory, economic, and social concerns [4]. However, hybrid UCB banking has been selected as a preferred model among some current and potential UCB donors [43]. Some challenges persist in developing directed-family cord blood banking for those families who are pregnant and have an existing child or a known risk for producing a child affected by a disease that could be cured by allogeneic HSC transplantation [4]. Conclusion Cord blood transplantation and banking have matured greatly in the first 25 years of application. It is obvious that cord blood banking models continue to be controversial and may continue to morph as the need for stored units increases worldwide. How UCB expansion technologies impact patient outcomes and usage may also factor into banking demands. As new fields of regenerative medicine test UCB as a potential source of reparative stem cells, even greater demand may be placed on the banking industry. It is anticipated that cord blood transplantation and banking will continue to advance along with the scientific progress.

12 Acknowledgements None.

13 References **1. Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122(4): Overview of the field of cord blood banking with suggested areas for continuing improvement. Provides concise review of the first patient to undergo a cord blood transplant and descibes how the field quickly emerged and evolved to the current state. 2. Gluckman E, Broxmeyer HA, Auerbach AD, Friedman HS, Douglas GW, Devergie A, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. The New England Journal of Medicine. 1989;321(17): Rubinstein P, Adamson JW, Stevens C. The Placental/Umbilical Cord Blood Program of the New York Blood Center. A Progress Report. Annals of the New York Academy of Sciences. 1999;872:328-34; discussion Gluckman E, Ruggeri A, Rocha V, Baudoux E, Boo M, Kurtzberg J, et al. Family-directed umbilical cord blood banking. Haematologica. 2011;96(11): Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. The New England Journal of Medicine. 1996;335(3): Rocha V, Wagner JE, Jr., Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, et al. Graftversus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. The New England Journal of Medicine. 2000;342(25): Herr AL, Kabbara N, Bonfim CM, Teira P, Locatelli F, Tiedemann K, et al. Long-term follow-up and factors influencing outcomes after related HLA-identical cord blood

14 transplantation for patients with malignancies: an analysis on behalf of Eurocord-EBMT. Blood. 2010;116(11): Eapen M, Rubinstein P, Zhang MJ, Stevens C, Kurtzberg J, Scaradavou A, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison study. Lancet. 2007;369(9577): Wagner JE, Eapen M, Carter SL, Haut PR, Peres E, Schultz KR, et al. No Survival Advantage After Double Umbilical Cord Blood (UCB) Compared to Single UCB Transplant in Children with Hematological Malignancy: Results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial. ASH Annual Meeting Abstracts. 2012;120(21): Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. The New England Journal of Medicine. 2001;344(24): Cohen YC, Scaradavou A, Stevens CE, Rubinstein P, Gluckman E, Rocha V, et al. Factors affecting mortality following myeloablative cord blood transplantation in adults: a pooled analysis of three international registries. Bone Marrow Transplantation. 2011;46(1):70-6. *12. Ooi J, Takahashi S, Tomonari A, Tsukada N, Konuma T, Kato S, et al. Unrelated cord blood transplantation after myeloablative conditioning in adults with acute myelogenous leukemia. Biology of blood and marrow transplantation : Journal of the American Society for Blood and Marrow Transplantation. 2008;14(12): Provides a brief overview of changes in cord blood unit selection and methods to expand cord blood stem cells for transplantation. *13. Cutler C, Ballen KK. Improving outcomes in umbilical cord blood transplantation: State of the Art. Blood Reviews. 2012;26(6):241-6.

15 Provides a brief overview of changes in cord blood unit selection and methods to expand cord blood stem cells for transplantation. 14. Cutler C, Stevenson K, Kim HT, Brown J, McDonough S, Herrera M, et al. Double umbilical cord blood transplantation with reduced intensity conditioning and sirolimusbased GVHD prophylaxis. Bone Marrow Transplantation. 2011;46(5): Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood. 2011;117(8): Sauter C, Abboud M, Jia X, Heller G, Gonzales AM, Lubin M, et al. Serious infection risk and immune recovery after double-unit cord blood transplantation without antithymocyte globulin. Biology of blood and marrow transplantation : Journal of the American Society for Blood and Marrow Transplantation. 2011;17(10): *17. Broxmeyer HE. Enhancing engraftment of cord blood cells via insight into the biology of stem/progenitor cell function. Annals of the New York Academy of Sciences. 2012;1266: Provides an overview of multiple strategies for expanding cord blood stem cells primarily in preclinical model systems. **18. Delaney C, Bollard CM, Shpall EJ. Cord blood graft engineering. Biology of blood and marrow transplantation : Journal of the American Society for Blood and Marrow Transplantation. 2013;19(1 Suppl):S74-8. An outstanding overview of the current approaches to expanding cord blood stem cells ex vivo to enhance in vivo engraftment. 19. Delaney C, Varnum-Finney B, Aoyama K, Brashem-Stein C, Bernstein ID. Dosedependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. Blood. 2005;106(8):

16 20. Delaney C, Heimfeld S, Brashem-Stein C, Voorhies H, Manger RL, Bernstein ID. Notchmediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nature Medicine. 2010;16(2): Robinson SN, Ng J, Niu T, Yang H, McMannis JD, Karandish S, et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplantation. 2006;37(4): *22. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, et al. Cordblood engraftment with ex vivo mesenchymal-cell coculture. The New England Journal of Medicine. 2012;367(24): First human clinical trial to demonstrate improved engraftment neutrophils and platelet times for cord blood stem cells expanded on mesenchymal cells and then transplanted into adult patients. 23. de Lima M, McMannis J, Gee A, Komanduri K, Couriel D, Andersson BS, et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: a phase I/II clinical trial. Bone Marrow Transplantation. 2008;41(9): Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, Sutton SE, et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science. 2010;329(5997): *25. Butler JM, Gars EJ, James DJ, Nolan DJ, Scandura JM, Rafii S. Development of a vascular niche platform for expansion of repopulating human cord blood stem and progenitor cells. Blood. 2012;120(6): Novel preclinical study approach to expanding cord blood stem cells using modified human umbilical vein endothelial cells as a supportive monolayer. 26. Corselli M, Chin CJ, Parekh C, Sahaghian A, Wang W, Ge S, et al. Perivascular support of human hematopoietic stem/progenitor cells. Blood. 2013;121(15):

17 27. Frassoni F, Gualandi F, Podesta M, Raiola AM, Ibatici A, Piaggio G, et al. Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. The Lancet Oncology. 2008;9(9): *28. Rocha V, Labopin M, Ruggeri A, Podesta M, Gallamini A, Bonifazi F, et al. Unrelated cord blood transplantation: outcomes after single-unit intrabone injection compared with double-unit intravenous injection in patients with hematological malignancies. Transplantation. 2013;95(10): Report on the results of a direct comparison of cord blood cells administered via direct intra-bone injections versus a double cord blood unit transplant. Discusses how the present results need to be further evaluated using more standard approaches to patient care and transplantation protocols. 29. Goessling W, Allen RS, Guan X, Jin P, Uchida N, Dovey M, et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell. 2011;8(4): Hoggatt J, Singh P, Sampath J, Pelus LM. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood. 2009;113(22): North TE, Goessling W, Walkley CR, Lengerke C, Kopani KR, Lord AM, et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature. 2007;447(7147): Pelus LM, Hoggatt J, Singh P. Pulse exposure of haematopoietic grafts to prostaglandin E2 in vitro facilitates engraftment and recovery. Cell Proliferation. 2011;44 Suppl 1:22-9. *33. Cutler C, Multani P, Robbins D, Kim HT, Le T, Hoggatt J, et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood. 2013;122(17): Very recent report on the improved engraftment provided by prostaglandin treated cord blood stem cells upon transplantation into human subjects.

18 34. Robinson SN, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, et al. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rgamma(null) mice. Experimental Hematology. 2012;40(6): Christopherson KW, 2nd, Hangoc G, Mantel CR, Broxmeyer HE. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science. 2004;305(5686): Farag SS, Srivastava S, Messina-Graham S, Schwartz J, Robertson MJ, Abonour R, et al. In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem cells and development. 2013;22(7): *37. Pelosi E, Castelli G, Testa U. Human umbilical cord is a unique and safe source of various types of stem cells suitable for treatment of hematological diseases and for regenerative medicine. Blood Cells, Molecules & Diseases. 2012;49(1):20-8. Concise overview of various stem cell populations for multiple lineages of cells that may be useful in regenerative medicine treatments. **38. Ilic D, Miere C, Lazic E. Umbilical cord blood stem cells: clinical trials in nonhematological disorders. British Medical Bulletin. 2012;102: Outstanding concise overview of the clinical trials of umbilical cord blood cells for nonhematologic conditions. *39. Carroll J. Human cord blood for the hypoxic-ischemic neonate. Pediatric Research. 2012;71(4 Pt 2): Presents evidence from preclinical studies performed with umbilical cord blood in rodents exposed to hypoxia-ischemia that supports consideration of human clinical trials. *40. Liao Y, Cotten M, Tan S, Kurtzberg J, Cairo MS. Rescuing the neonatal brain from hypoxic injury with autologous cord blood. Bone Marrow Transplantation. 2013;48(7):

19 Timely analysis of the results of preclinical animal models of human hypoxia-ischemia and provides rationale for considering human clinical trials of autologous cord blood transplantation for neonates with hypoxic-ischemic injury. 41. Guindi, E.S. in Broxmeyer, H. E.(ed), Cord Blood: Biology, Transplantation, Banking, and Regulation. Bethesda, MD. AABB Press, 2011, pp Rosenthal J, Woolfrey AE, Pawlowska A, Thomas SH, Appelbaum F, Forman S. Hematopoietic cell transplantation with autologous cord blood in patients with severe aplastic anemia: an opportunity to revisit the controversy regarding cord blood banking for private use. Pediatric Blood & Cancer. 2011;56(7): Wagner AM, Krenger W, Suter E, Ben Hassem D, Surbek DV. High acceptance rate of hybrid allogeneic-autologous umbilical cord blood banking among actual and potential Swiss donors. Transfusion. 2013;53(7):

20 Table Table. Clinical trials using UCB stem cells in therapy of non-hematological disorders. Condition ClinicalTrials.gov Identifier No Alzheimer s disease NCT Autism NCT Bronchopulmonary dysplasia NCT Burns NCT Cartilage injury, osteoarthritis NCT Cerebral palsy NCT ; NCT Critical limb ischemia NCT Diabetes NCT ; NCT ; NCT ; 4 NCT Epidermolysis bullosa NCT ; NCT ; NCT Hearing loss NCT Inborn metabolic disorders NCT a ; NCT a; NCT ; 8 NCT ;NCT ; NCT ; NCT ; NCT Osteopetrosis NCT ; NCT ; NCT Solid tumors NCT ; NCT Stroke NCT SLE, systemic sclerosis NCT SLE, systemic lupus erythematosus. a Clinical trials that involve both hematological and non-hematological disorders. reprinted with permission from Ilic D, et al. Umbilical cord blood stem cells: clinical trials in non-hematological disorders. British medical bulletin. 2012;102:43-57.

Cord Blood: Research Progress and Future Promise

Cord Blood: Research Progress and Future Promise Cord Blood: Research Progress and Future Promise By Al Staropoli, AABB Contributing Writer Sue Fister found out she had leukemia when she was 50 years old. Doctors suggested a bone marrow transplant as

More information

Double cord blood transplantation

Double cord blood transplantation DCTH - 2 2013-113-121 REVIEW Double cord blood transplantation R. Angarano, I. Donnini, B. Bartolozzi, A. Bosi Ematologia, Azienda Ospedaliera Universitaria Careggi, Università di Firenze, Italy SUMMARY

More information

Placental/Umbilical Cord Blood as a Source of Stem Cells. Original Policy Date

Placental/Umbilical Cord Blood as a Source of Stem Cells. Original Policy Date MP 7.01.38 Placental/Umbilical Cord Blood as a Source of Stem Cells Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013

More information

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE

UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE HIND AL HUMAIDAN, MD,FRCPA Director, Blood Bank (Donor & Transfusion Services) and Stem Cell Cord Blood Bank Consultant Hematopathologist INTRODUCTION

More information

Do you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life Sciences @jessbiopharma

Do you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life Sciences @jessbiopharma 1 Who is the most influential figure in cord blood around the world? What is the biggest challenge to overcome in the use of cord blood as a source of stem cells? We asked 10 leading experts in the cord

More information

Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit. Karen Ballen, MD Massachusetts General Hospital June, 2012

Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit. Karen Ballen, MD Massachusetts General Hospital June, 2012 Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit Karen Ballen, MD Massachusetts General Hospital June, 2012 OUTLINE Cell Dose HLA Typing HLA C and KIR HLA Antibodies ABO and Racial/Ethnic

More information

STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE

STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE What are Stem Cells? Stem cells are the basic building blocks of all the cells, tissues and organs in the human body. The role of the stem

More information

Selecting an appropriately matched donor for hematopoietic

Selecting an appropriately matched donor for hematopoietic Transplant Outcomes in Acute Leukemia (I) Mary Eapen a and John E. Wagner b Umbilical cord blood (UCB) has gradually emerged over the last decade as an alternative source of hematopoietic cells for transplantation

More information

Placental and Umbilical Cord Blood as a Source of Stem Cells

Placental and Umbilical Cord Blood as a Source of Stem Cells Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2015 Origination: 12/2001 Next Review: 12/2016 Policy Blue Cross and Blue Shield of Kansas City (Blue

More information

Umbilical Cord Blood Stem Cells Current Status & Future Potential

Umbilical Cord Blood Stem Cells Current Status & Future Potential Umbilical Cord Blood Stem Cells Current Status & Future Potential Natasha Ali Assistant Professor Haematology Department of Pathology & Laboratory Medicine/Oncology The Aga Khan University Email: natasha.ali@aku.edu

More information

Placental and Umbilical Cord Blood as a Source of Stem Cells

Placental and Umbilical Cord Blood as a Source of Stem Cells Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2013 Origination: 12/2001 Next Review: 12/2014 Policy Blue Cross and Blue Shield of Kansas City (Blue

More information

Umbilical cord blood transplantation

Umbilical cord blood transplantation Review article http://dx.doi.org/10.3345/kjp.2012.55.7.219 Korean J Pediatr 2012;55(7):219-223 eissn 1738-1061 pissn 2092-7258 Umbilical cord blood transplantation Hong Hoe Koo, MD 1, Hyo Seop Ahn, MD

More information

Selection of the Optimal Umbilical Cord Blood Unit

Selection of the Optimal Umbilical Cord Blood Unit Karen Ballen, MD Selection of the Optimal Umbilical Cord Blood Unit Massachusetts General Hospital September, 2013 OUTLINE Cell Dose HLA Match Allele Level HLA C KIR Directional Mismatch NIMA HLA Antibodies

More information

Pr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose

Pr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose Pr Eliane Gluckman, MD, FRCP, Hospital Saint Louis, University Paris- Diderot, France Should Haplo-identical transplantation be preferred to cord blood in patients without a matched donor? Disclosure of

More information

Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients

Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant Recipients Filippo Milano, 1 J. Lee Nelson, 1, 2 Colleen Delaney 1,3 1 Clinical Research Division, Fred Hutchinson Cancer Research

More information

Placental and Umbilical Cord Blood as a Source of Stem Cells

Placental and Umbilical Cord Blood as a Source of Stem Cells Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2014 Origination: 12/2001 Next Review: 12/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue

More information

Navelstrengbloed tegen kanker

Navelstrengbloed tegen kanker Navelstrengbloed tegen kanker THERAPIEDAG 2008: "Zorgtrajecten in kanker" Zaterdag 27 september 2008 Gasthuisberg, Leuven. Hélène Schoemans, MD KUL, Stem Cell Institute Leuven Cord blood Collection and

More information

Transplantation of cord blood stem cells from related or unrelated donors is considered investigational in all other situations.

Transplantation of cord blood stem cells from related or unrelated donors is considered investigational in all other situations. MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Placental and Umbilical Cord Blood as a Source of Stem Cells

More information

UMBILICAL CORD BLOOD STATISTICS

UMBILICAL CORD BLOOD STATISTICS UMBILICAL CORD BLOOD STATISTICS INTRODUCTION Stem cells are the next frontier in medicine. Stem cells are thought to have great therapeutic and biotechnological potential. This will not only to replace

More information

4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.

4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements. WMDA Policy Statement on the Utility of Autologous or Family Cord Blood Unit Storage The WMDA Board adopted this policy on 25 th of May 2006. Policy updated _April 2011 The Cord Blood Working Group and

More information

THE NEW ZEALAND MEDICAL JOURNAL

THE NEW ZEALAND MEDICAL JOURNAL THE NEW ZEALAND MEDICAL JOURNAL Vol 118 No 1208 ISSN 1175 8716 Private umbilical cord blood banking: a biological insurance of dubious future benefit! Michael Sullivan, Peter Browett, Nigel Patton In its

More information

Stem cells from Cord Blood: Myths, reality and potential. Elisabeth Semple, PhD Scientific Director Cells for Life Cord Blood Institute

Stem cells from Cord Blood: Myths, reality and potential. Elisabeth Semple, PhD Scientific Director Cells for Life Cord Blood Institute Stem cells from Cord Blood: Myths, reality and potential Elisabeth Semple, PhD Scientific Director Cells for Life Cord Blood Institute Learning objectives Understand the current usage of stem cells from

More information

Umbilical Cord Blood Transplantation

Umbilical Cord Blood Transplantation Umbilical Cord Blood Transplantation V Rocha MD, PhD Hopital Saint Louis, Paris University 7 CIBMTR Milwaukee Umbilical Cord blood transplantation Background History Clinical results in children and adults

More information

Name of Policy: Placental/Umbilical Cord Blood as a Source of Stem Cells

Name of Policy: Placental/Umbilical Cord Blood as a Source of Stem Cells Name of Policy: Placental/Umbilical Cord Blood as a Source of Stem Cells Policy #: 439 Latest Review Date: September 2014 Category: Medical Policy Grade: A Background/Definitions: As a general rule, benefits

More information

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY

POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY Original Issue Date (Created): 4/1/2011 Most Recent Review Date (Revised): 3/24/2015 Effective Date: 6/1/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER

More information

What we will discuss today

What we will discuss today Umbilical cord blood banking It s Utility? Dr. Nita Radhakrishnan Pediatric Hematology Oncology Unit, Sir Ganga Ram Hospital, New Delhi What we will discuss today What are stem cells? What are the sources

More information

Section: Transplant Last Reviewed Date: January 2015. Policy No: 45.16 Effective Date: April 1, 2015

Section: Transplant Last Reviewed Date: January 2015. Policy No: 45.16 Effective Date: April 1, 2015 Medical Policy Manual Topic: Placental and Umbilical Cord Blood as a Source of Stem Cells Date of Origin: December 2009 Section: Transplant Last Reviewed Date: January 2015 Policy No: 45.16 Effective Date:

More information

A Public Cord Blood Bank for South Africa? i

A Public Cord Blood Bank for South Africa? i No. 42/2007 A Public Cord Blood Bank for South Africa? i By Dr Robert Crookes MBChB (Wits), Dip. Internal Medicine (American Board of Internal Medicine, USA) Transfusion Medicine Consultant. South African

More information

So, get comfortable and enjoy finding out what the greatest achievements and challenges are facing the industry today.

So, get comfortable and enjoy finding out what the greatest achievements and challenges are facing the industry today. 1 Who is the most influential figure in cord blood around the world? What do you think has been the biggest achievement within the cord blood sector? Which is the most important development in cord blood

More information

Corporate Medical Policy Cord Blood as a Source of Stem Cells

Corporate Medical Policy Cord Blood as a Source of Stem Cells Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description

More information

Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa

Pros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Pros and Cons of Stem Cell Sources and their availability in Africa Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Introduction The ability to perform a haematopoietic stem

More information

5. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.

5. All cord blood banks should be subject to the same standards, regulations and accreditation requirements. WMDA Policy Statement for the Utility of Autologous or Family Cord Blood Unit Storage (This policy statement has been approved and adopted by the WMDA board on the 25 th of May 2006) The Cord Blood Registries

More information

In contrast to the very high transplant-related

In contrast to the very high transplant-related Cord Blood: an Alternative Stem Cell Source or a New Standard? Juliet N. BARKER Memorial Sloan-Kettering Cancer Center, NY, ABD In contrast to the very high transplant-related mortality (TRM) associated

More information

UMBILICAL-CORD BLOOD TRANSPLANTATION FOR THE TREATMENT OF CANCER

UMBILICAL-CORD BLOOD TRANSPLANTATION FOR THE TREATMENT OF CANCER UMBILICAL-CORD BLOOD TRANSPLANTATION FOR THE TREATMENT OF CANCER Juliet N. Barker* and John E. Wagner Haematopoietic stem-cell transplantation is used to treat many haematological cancers, but is limited

More information

Saving your baby s s cord blood: Is this good insurance?

Saving your baby s s cord blood: Is this good insurance? Saving your baby s s cord blood: Is this good insurance? 32 th SEMINAR ON PERINATAL MEDICINE CONTROVERSIES IN PERINATAL MEDICINE: EVIDENCE FOR CURRENT PRACTICE Sante Fe, New Mexico Mervin C. Yoder, MD

More information

Discover the Possibilities Born With Your Baby

Discover the Possibilities Born With Your Baby Discover the Possibilities Born With Your Baby Your Simple Guide to Saving Cord Blood The Power and Promise The lifesaving power of cord blood and regenerative healing potential of cord blood and cord

More information

Statement of Joanne Kurtzberg, M.D.

Statement of Joanne Kurtzberg, M.D. Statement of Joanne Kurtzberg, M.D. President of the Cord Blood Association Jerome Harris Distinguished Professor of Pediatrics and Pathology Chief Scientific Officer and Medical Director, Robertson Clinical

More information

PT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank

PT CordLife Indonesia Premium Cordblood Bank. PT CordLife Indonesia Premium Cordblood Bank Cordblood Stem Cells and The Role of Cordblood Bank in Supporting Stem Cells Research Presentation Overview Company profile Haematopoietic stem cells in cordblood What we can do to help 1 2 PT CordLife

More information

Saving Your Baby s Cord Blood

Saving Your Baby s Cord Blood Saving Your Baby s Cord Blood An Important Pregnancy Decision 1-888-CORD BLOOD HEALTHY FUTURES ARE Born at CBR For every parent who wishes they could do more to protect their family s health, there s Cord

More information

Cord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program

Cord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program Cord Blood: that other stem cell source Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program CBMTG April 2012 The problem: In order to perform a BMT from one person to another one needs

More information

Cord Blood Biology and Transplantation

Cord Blood Biology and Transplantation Cord Blood Biology and Transplantation Yossi Cohen MD MSc and Arnon Nagler MD Institute of Hematology, Department of Bone Marrow Transplantation and Cord Blood Bank, Sheba Medical Center, Tel Hashomer,

More information

Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris

Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris Background Hematopoietic stem cell transplantation (HSCT) is

More information

Cord Blood Stem Cell Transplantation

Cord Blood Stem Cell Transplantation LEUKEMIA LYMPHOMA MYELOMA FACTS Cord Blood Stem Cell Transplantation No. 2 in a series providing the latest information on blood cancers Highlights Umbilical cord blood, like bone marrow and peripheral

More information

Hematopoiesis i starts from. HPC differentiates t to sequentially more mature. HPC circulate in very low

Hematopoiesis i starts from. HPC differentiates t to sequentially more mature. HPC circulate in very low Upstate Cord Blood Bank Hematopoietic Progenitor Cells Hematopoiesis i starts from self renewing HPC HPC differentiates t to sequentially more mature blood cells HPC circulate in very low numbers in adults

More information

Therapeutic Potential of Cells Derived from Gestational Tissues: A coming of age. Dr Roisin Deane Cell Care Australia Pty Ltd

Therapeutic Potential of Cells Derived from Gestational Tissues: A coming of age. Dr Roisin Deane Cell Care Australia Pty Ltd Therapeutic Potential of Cells Derived from Gestational Tissues: A coming of age Dr Roisin Deane Cell Care Australia Pty Ltd What are Gestational Stem Cells? Stem cells isolated from the gestational tissues

More information

A Cure for Sickle Cell Anemia and Thalassemia

A Cure for Sickle Cell Anemia and Thalassemia IV Simpósio Internacional de Hemoglobinopatias A Cure for Sickle Cell Anemia and Thalassemia Bertram Lubin, MD and Mark Walters, MD 4 September 2007 Topics to be covered Cord blood: Importance and biology

More information

Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape

Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape GENReports: Market & Tech Analysis Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us

More information

Sibling Donor Cord Blood Transplantation for Thalassemia Major: Experience of the Sibling Donor Cord Blood Program

Sibling Donor Cord Blood Transplantation for Thalassemia Major: Experience of the Sibling Donor Cord Blood Program Sibling Donor Cord Blood Transplantation for Thalassemia Major: Experience of the Sibling Donor Cord Blood Program MARK C. WALTERS, LYNN QUIROLO, ELIZABETH T. TRACHTENBERG, SANDIE EDWARDS, LISA HALE, JOANNA

More information

Determinants of Engraftment after Double-Unit Cord Blood Transplantation

Determinants of Engraftment after Double-Unit Cord Blood Transplantation In: Broxmeyer HE, ed. Cord Blood: Biology, Transplantation, Banking, and Regulation Bethesda, MD: AABB Press, 2011 26 Determinants of Engraftment after Double-Unit Cord Blood Transplantation Doris M. Ponce,

More information

Program Co-Chairmen: Dr. John Wagner, University of Minnesota Dr. Richard Champlin, M.D. Anderson Cancer Center

Program Co-Chairmen: Dr. John Wagner, University of Minnesota Dr. Richard Champlin, M.D. Anderson Cancer Center (last updated May 13, 2004) This is an activity offered by CBBS, a CMA accredited provider. Physicians attending this course may report up to 13.25 hours of Category 1 credits toward the California Medical

More information

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine

Hematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells

More information

In a number of genetic, hematologic, and oncologic

In a number of genetic, hematologic, and oncologic AMERICAN ACADEMY OF PEDIATRICS Cord Blood Banking for Potential Future Transplantation: Subject Review ABSTRACT. In recent years, umbilical cord blood, which contains a large number of hematopoietic stem

More information

Not All Stem Cells are the Same

Not All Stem Cells are the Same Cord Blood Banking and Transplantation Jennifer Willert, M.D. Hematology/Oncology Blood and Marrow Transplant Rady Children s Hospital San Diego Clinical Professor UCSD Not All Stem Cells are the Same

More information

CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION

CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION Chapter 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION 1.1 OVERVIEW OF THE CORD BLOOD TRANSPLANTATION STUDY Bone marrow transplantation

More information

CORD BLOOD TRANSPLANTATION: PAST, PRESENT AND FUTURE

CORD BLOOD TRANSPLANTATION: PAST, PRESENT AND FUTURE CORD BLOOD TRANSPLANTATION: PAST, PRESENT AND FUTURE Dennis M. Todd, Ph.D. The New Jersey Cord Blood Bank a Division of Bergen Community Regional Blood Center Montvale, NJ Hematopoietic Stem Cell Transplantation

More information

Umbilical Cord Blood: An Alternative Allogeneic Stem Cell Source for Transplantation

Umbilical Cord Blood: An Alternative Allogeneic Stem Cell Source for Transplantation Umbilical Cord Blood: An Alternative Allogeneic Stem Cell Source for Transplantation Mary J. Laughlin, MD Associate Professor of Medicine and Pathology Dr. Donald and Ruth Weber Goodman Professor of Innovative

More information

STEM CELLS : A THERAPEUTIC REVOLUTION JACQUES KADOCH ROBERT HEMMINGS MARINELA MANDRA

STEM CELLS : A THERAPEUTIC REVOLUTION JACQUES KADOCH ROBERT HEMMINGS MARINELA MANDRA STEM CELLS : A THERAPEUTIC REVOLUTION JACQUES KADOCH ROBERT HEMMINGS MARINELA MANDRA OVO CLINIC I 8000 BLVD DECARIE, MONTREAL QC H4P 2S4 I 514.798.2000 I OVOCLINIC.COM 2 a therapeutic revolution As the

More information

CIGNA HEALTHCARE COVERAGE POSITION

CIGNA HEALTHCARE COVERAGE POSITION CIGNA HEALTHCARE COVERAGE POSITION Subject Umbilical Cord Blood Banking Table of Contents Coverage Position... 1 General Background... 1 Coding/Billing Information... 3 References... 3 Revised Date...

More information

International Journal of Stem Cell Research and Transplantation (IJST) ISSN 2328-3548

International Journal of Stem Cell Research and Transplantation (IJST) ISSN 2328-3548 International Journal of Stem Cell Research and Transplantation (IJST) ISSN 2328-3548 Umbilical Cord Blood Transplantation: Clinical Challenges Shilpa Sharma & Gurudutta Gangenahalli * Review Article Division

More information

10 th Annual International Cord Blood Transplantation Symposium June 7-9, 2012 Preliminary Scientific Program. Thursday, June 7

10 th Annual International Cord Blood Transplantation Symposium June 7-9, 2012 Preliminary Scientific Program. Thursday, June 7 10 th Annual International Cord Blood Transplantation Symposium June 7-9, 2012 Preliminary Scientific Program Thursday, June 7 7:00 8:00 AM Breakfast in Exhibit Hall Session IA 8:00 10:00 AM Advances in

More information

One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers

One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers The new england journal of medicine Original Article One-Unit versus Two-Unit Cord-Blood Transplantation for Hematologic Cancers John E. Wagner, Jr., M.D., Mary Eapen, M.B., B.S., Shelly Carter, D.Sc.,

More information

Unrelated donor umbilical cord blood transplantation for the treatment of hematologic malignancies Craig Sauter and Juliet N.

Unrelated donor umbilical cord blood transplantation for the treatment of hematologic malignancies Craig Sauter and Juliet N. Unrelated donor umbilical cord blood transplantation for the treatment of hematologic malignancies Craig Sauter and Juliet N. Barker Adult Allogeneic Bone Marrow Transplantation Service, Memorial Sloan-Kettering

More information

Corporate Medical Policy Cord Blood as a Source of Stem Cells

Corporate Medical Policy Cord Blood as a Source of Stem Cells Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description

More information

SAVE A LIFE... BY GIVING LIFE!

SAVE A LIFE... BY GIVING LIFE! SAVE A LIFE... BY GIVING LIFE! FOLLOW US ON: HÉMA-QUÉBEC PUBLIC CORD BLOOD BANK www.hema-quebec.qc.ca Scan this code with your smart phone to access the page Register to the Public Cord Blood Bank on the

More information

Cord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD

Cord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD Cord Blood Banking Scott N. Furlan, MD Ellen S.Plummer, MD Overview Background Biology of Stem Cell Transplant Opportunities i at Parkland Logistics of Banking Potential Barriers Indications for HCT Cancer

More information

UMBILICAL CORD BLOOD HARVESTING & STORAGE

UMBILICAL CORD BLOOD HARVESTING & STORAGE Protocol: TRP009 Effective Date: October 14, 2013 UMBILICAL CORD BLOOD HARVESTING & STORAGE Table of Contents Page COMMERCIAL, MEDICARE & MEDICAID COVERAGE RATIONALE... 1 BACKGROUND... 2 CLINICAL EVIDENCE...

More information

Milestones in umbilical cord blood transplantation

Milestones in umbilical cord blood transplantation historical review Milestones in umbilical cord blood transplantation Eliane Gluckman, Annalisa Ruggeri, Fernanda Volt, Renato Cunha, Karim Boudjedir and Vanderson Rocha Eurocord, Assistance publique des

More information

Umbilical Cord Blood (UCB) Transplantation: An Alternative to the Use of Unrelated Volunteer Donors?

Umbilical Cord Blood (UCB) Transplantation: An Alternative to the Use of Unrelated Volunteer Donors? Umbilical Cord Blood (UCB) Transplantation: An Alternative to the Use of Unrelated Volunteer Donors? Juliet N. Barker Memorial Sloan-Kettering Cancer Center, New York, NY Cryopreserved umbilical cord blood

More information

Basic Science in Medicine

Basic Science in Medicine Medical Journal of th e Islamic Republic of Iran Volume 18 Number 3 Fall 1383 November 2004 Basic Science in Medicine ] EXPANSION OF HUMAN CORD BLOOD PRIMITIVE PROGENITORS IN SERUM-FREE MEDIA USING HUMAN

More information

Phone: +44 20 8123 2220 Fax: +44 207 900 3970 office@marketpublishers.com http://marketpublishers.com

Phone: +44 20 8123 2220 Fax: +44 207 900 3970 office@marketpublishers.com http://marketpublishers.com Global Stem Cell Umbilical Cord Blood (UCB) Market (Storage Service, Therapeutics, Application, Geography) - Size, Share, Global Trends, Analysis, Opportunities, Growth, Intelligence and Forecast, 2012-2020

More information

GRANIX (tbo-filgrastim)

GRANIX (tbo-filgrastim) RATIONALE FOR INCLUSION IN PA PROGRAM Background Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils. A person with severe neutropenia has an absolute neutrophil

More information

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research

guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research infoaging guides BIOLOGY OF AGING STEM CELLS An introduction to aging science brought to you by the American Federation for Aging Research WHAT ARE STEM CELLS? Stem cells are cells that, in cell cultures

More information

Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture

Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture original article Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture Marcos de Lima, M.D., Ian McNiece, Ph.D., Simon N. Robinson, Ph.D., Mark Munsell, M.S., Mary Eapen, M.D., Mary Horowitz,

More information

The donor search: the best donor or cord blood unit

The donor search: the best donor or cord blood unit The donor search: the best donor or cord blood unit Dr Bronwen Shaw Consultant in haematopoietic cell transplantation Royal Marsden Hospital /Anthony Nolan Overview Where do we find donors/units for transplantation

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll

More information

The availability of haematopoietic stem or progenitor

The availability of haematopoietic stem or progenitor Update Article Umbilical Cord Blood Transplantation: Newer Trends MB Agarwal Abstract During last ten years, over 4000 umbilical cord blood transplantations have been performed worldwide. The interest

More information

Cord Blood Market Trends, circa 2014

Cord Blood Market Trends, circa 2014 GENReports: Market & Tech Analysis Cord Blood Market Trends, circa 2014 > Enal Razvi, Ph.D. Managing Director Select Biosciences, Inc. enal@selectbio.us Topic Introduction and Scope The focus of this GEN

More information

The Therapeutic Potential of Human Umbilical Cord Blood Transplantation for Neonatal Hypoxic-Ischemic Brain Injury and Ischemic Stroke

The Therapeutic Potential of Human Umbilical Cord Blood Transplantation for Neonatal Hypoxic-Ischemic Brain Injury and Ischemic Stroke The Therapeutic Potential of Human Umbilical Cord Blood Transplantation for Neonatal Hypoxic-Ischemic Brain Injury and Ischemic Stroke a,b* b,c a a b b b b a b a b c 430 Wang et al. Acta Med. Okayama Vol.

More information

Saving umbilical blood from newborn infants: the clinical potential, economics and ethics

Saving umbilical blood from newborn infants: the clinical potential, economics and ethics Saving umbilical blood from newborn infants: the clinical potential, economics and ethics Abstract: Umbilical cord blood is the blood remaining in the placenta and umbilical cord after childbirth. It had

More information

New insights into cord blood stem cell transplantation William Tse a,c, Kevin D. Bunting b,c and Mary J. Laughlin b,c,d

New insights into cord blood stem cell transplantation William Tse a,c, Kevin D. Bunting b,c and Mary J. Laughlin b,c,d New insights into cord blood stem cell transplantation William Tse a,c, Kevin D. Bunting b,c and Mary J. Laughlin b,c,d a Division of Medical Oncology, Department of Medicine, University of Colorado Health

More information

Preparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between

Preparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between Preparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program ISCT 2012 Disclosures: none The problem:

More information

Disclosures. I have no disclosures.

Disclosures. I have no disclosures. Not Your Own Marrow Jenni Krajewski, MD Clinical Assistant Professor, Rutgers New Jersey Medical School Attending Physician, Pediatric Blood and Marrow Transplantation The Institute for Pediatric Cancer

More information

5 Frequently Asked Questions About Adult Stem Cell Research

5 Frequently Asked Questions About Adult Stem Cell Research 5 Frequently Asked Questions About Adult Stem Cell Research Stem cells are often referred to in the sociopolitical realm with some level of controversy and beyond that, some level of confusion. Many researchers

More information

Cigna Medical Coverage Policy

Cigna Medical Coverage Policy Cigna Medical Coverage Policy Subject Umbilical Cord Blood Banking Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 3 References... 4 Effective Date... 6/15/2014

More information

It s not something you want to think about, but it s something you want to prepare for.

It s not something you want to think about, but it s something you want to prepare for. It s not something you want to think about, but it s something you want to prepare for. StemCyte cord blood banking offers your family a new lifesaving treatment alternative Why Bank Take the once-in-alifetime

More information

Umbilical cord blood transplantation: a maturing technology

Umbilical cord blood transplantation: a maturing technology HEMATOPOIETIC STEM CELL TRANSPLANTATION I: EXPLOITING ALTERNATIVE DONORS Umbilical cord blood transplantation: a maturing technology Betul Oran 1 and Elizabeth Shpall 1 1 Department of Stem Cell Transplantation

More information

The Types of stem cells: Totipotent Pluripotent Multipotent

The Types of stem cells: Totipotent Pluripotent Multipotent Stem Cells is the main material for building and regeneration of the body Stem cells are not differentiated and can transform to any cell of organism Stem cells are capable of indefinite renewal through

More information

The Facts about Cord Blood

The Facts about Cord Blood The Facts about Cord Blood Dear Future Mom and/or Dad, All of us at CorCell would like to give you a big CONGRATULATIONS on your new baby! Now that you are expecting, you have probably heard about saving

More information

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood

Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood [Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,

More information

Reference: NHS England B04/P/a

Reference: NHS England B04/P/a Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation (HSCT) (All Ages): Revised Reference: NHS England B04/P/a 1 NHS England Clinical Commissioning Policy: Haematopoietic Stem Cell Transplantation

More information

STEM CELL FELLOWSHIP

STEM CELL FELLOWSHIP Module I: The Basic Principles of Stem Cells 1. Basics of Stem Cells a. Understanding the development of embryonic stem cells i. Embryonic stem cells ii. Embryonic germ cells iii. Differentiated stem cell

More information

DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT

DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT www.narayanahealth.org DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT About Narayana Health City Narayana Health, one of India's largest and the world's most economical healthcare service providers

More information

Vita 34 Parents Guide to umbilical Cord Blood Banking. secure first-class innovative

Vita 34 Parents Guide to umbilical Cord Blood Banking. secure first-class innovative Vita 34 Parents Guide to umbilical Cord Blood Banking secure first-class innovative Contents INTRODUCTION 3 THERAPEUTIC USES OF STEM CELLS 4 STEM CELLS IN CANCER TREATMENT STEM CELLS IN THE TREATMENT OF

More information

House Resolution No. 37

House Resolution No. 37 california legislature regular session House Resolution No. Introduced by Assembly Member Hill August, House Resolution No. Relative to umbilical cord blood banking. WHEREAS, Since the first umbilical

More information

Stem Cell Banking. Umbilical Cord. The Leading Cell Bank www.stemology.co.uk. Protect your family s future

Stem Cell Banking. Umbilical Cord. The Leading Cell Bank www.stemology.co.uk. Protect your family s future Protect your family s future The Leading Cell Bank www.stemology.co.uk Stem Cell Banking Umbilical Cord For women in their 1st, 2nd or 3rd Trimester of Pregnancy Introduction to Stemology Imagine you

More information

Umbilical Cord Blood Transplantation for the Treatment of Hematologic Malignancies

Umbilical Cord Blood Transplantation for the Treatment of Hematologic Malignancies Umbilical cord blood transplantation is a useful treatment in several types of hematologic malignancies. Gene Elling. St. Lucia. Photograph. Umbilical Cord Blood Transplantation for the Treatment of Hematologic

More information